Trials / Recruiting
RecruitingNCT06525597
Study of Stapokibart Injection in Patients With Allergic Rhinitis
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Stapokibart Injection in Patients With Allergic Rhinitis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Randomized, Double-blind, Placebo-controlled phase II clinical study evaluating the efficacy and safety of Stapokibart injection in patients with allergic rhinitis.
Detailed description
Allergic rhinitis (AR) is a non infectious chronic inflammatory disease of the nasal mucosa that is mainly mediated by immunoglobulin E (IgE) in atopic individuals exposed to allergens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Stapokibart Injection | IL-4Rα monoclonal antibody |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2024-09-30
- Primary completion
- 2025-10-30
- Completion
- 2025-10-30
- First posted
- 2024-07-29
- Last updated
- 2024-11-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06525597. Inclusion in this directory is not an endorsement.